Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TGTX 
TG Therapeutics Inc (TGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: TGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.5
1 Year Target Price $40.5
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.53% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.10B USD | Price to earnings Ratio 84.63 | 1Y Target Price 40.5 |
Price to earnings Ratio 84.63 | 1Y Target Price 40.5 | ||
Volume (30-day avg) 7 | Beta 1.88 | 52 Weeks Range 21.16 - 46.48 | Updated Date 09/14/2025 |
52 Weeks Range 21.16 - 46.48 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.32% | Operating Margin (TTM) 24.69% |
Management Effectiveness
Return on Assets (TTM) 9.72% | Return on Equity (TTM) 26.63% |
Valuation
Trailing PE 84.63 | Forward PE 42.92 | Enterprise Value 5104532114 | Price to Sales(TTM) 11.24 |
Enterprise Value 5104532114 | Price to Sales(TTM) 11.24 | ||
Enterprise Value to Revenue 11.24 | Enterprise Value to EBITDA 52.31 | Shares Outstanding 158666000 | Shares Floating 135140097 |
Shares Outstanding 158666000 | Shares Floating 135140097 | ||
Percent Insiders 9.73 | Percent Institutions 64.63 |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics, Inc. was founded in 2011. It is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. The company has evolved from a research-focused entity to one with a marketed product, though limited in scope.
Core Business Areas
- B-Cell Malignancies: Development and commercialization of therapies targeting B-cell malignancies, including lymphomas and leukemias. Formerly its primary focus.
- Autoimmune Diseases: Exploration of therapies for autoimmune diseases, expanding beyond its initial oncology focus.
Leadership and Structure
The leadership team includes Michael S. Weiss (Chairman and CEO). The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Ukoniq (umbralisib): Ukoniq is a PI3K inhibitor approved for relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). However, it was voluntarily withdrawn from the market in 2022. Competitors included other PI3K inhibitors and standard chemotherapy regimens. Revenue figures are no longer relevant due to market withdrawal.
- Briumvi (ublituximab-xiiy): Briumvi is an anti-CD20 monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Competitors include Ocrevus (ocrelizumab) by Roche, Kesimpta (ofatumumab) by Novartis, Tysabri (natalizumab) by Biogen, Mayzent (siponimod) by Novartis and Mavenclad (cladribine) by EMD Serono.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in oncology and autoimmune diseases, is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by innovation and unmet medical needs.
Positioning
TG Therapeutics is positioned as a company focused on developing and commercializing targeted therapies for B-cell malignancies and autoimmune diseases. The approval of Briumvi provides a foothold in the competitive MS market. The withdrawal of Ukoniq highlights the risks inherent in drug development and commercialization.
Total Addressable Market (TAM)
The global MS market is estimated to be worth billions of dollars. Briumvi's success depends on capturing a portion of this market through effective clinical results and market access.
Upturn SWOT Analysis
Strengths
- Approved product (Briumvi) for MS.
- Experience in B-cell targeted therapies.
- Established research and development capabilities.
- Experienced leadership team.
Weaknesses
- Past product withdrawal (Ukoniq) impacting reputation.
- Limited commercial infrastructure compared to larger pharmaceutical companies.
- Reliance on a single key product for revenue generation.
Opportunities
- Further expansion of Briumvi into other MS subtypes.
- Development of new therapies for B-cell malignancies and autoimmune diseases.
- Partnerships or collaborations to expand market reach.
- Potential for label expansion of Briumvi.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Pricing pressures and reimbursement challenges.
- Generic competition for existing products.
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
- BIIB
- SNY
- MRK
- PFE
- LLY
Competitive Landscape
TG Therapeutics faces strong competition from established pharmaceutical companies with greater resources and broader product portfolios. Briumvi's success will depend on its ability to differentiate itself from existing therapies and secure market access.
Growth Trajectory and Initiatives
Historical Growth: TG Therapeutics experienced growth with the approval of Ukoniq, but its subsequent withdrawal negatively impacted growth. The launch of Briumvi is expected to drive future growth.
Future Projections: Future growth is dependent on the successful commercialization of Briumvi and the development of new therapies. Analyst estimates vary based on market penetration assumptions.
Recent Initiatives: Recent initiatives include the commercial launch of Briumvi and ongoing clinical trials for other pipeline candidates.
Summary
TG Therapeutics is a biopharmaceutical company transitioning from a research-focused entity to a commercial one with Briumvi. The previous Ukoniq withdrawal creates risk. Briumvi's uptake in the MS market is critical for future success. Competition is fierce, and strategic partnerships may be necessary to expand reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 370 | Website https://www.tgtherapeutics.com |
Full time employees 370 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.